肺耐药蛋白在乳腺浸润性导管癌中的表达及与EGFR、HER-2的相关性

Expression of Lung-resistance Protein,Epidermal Growth Factor Receptor and HER-2 in Breast Infiltrating Duct Cancer and Its Clinical Significance

目的探讨肺耐药蛋白(lung-resistance protein,LRP)与促瘤因素表皮生长因子受体(epidermal growth factor receptor,EGFR)和HER-2在乳腺浸润性导管癌中的表达及其临床意义。方法采用免疫组化EnVision法,检测76例乳腺癌组织中LRP、EGFR和HER-2的表达。结果1)在乳腺癌组织中,LRP、EGFR、HER-2的表达率分别为35.53%、15.79%和25%,它们相互之间表达相关性不明显。2)随着肿瘤组织恶性程度的增高,LRP的表达明显降低(P=0.039)。3)LRP、EGFR、HER-2在淋巴结非转移组与转移组中的表达差异无统计学意义。结论LRP的表达在乳腺癌的恶性进展过程中起重要作用,诊断过程中结合该指标可更准确判断肿瘤恶性程度。

Objective To investigate expression of lung-resistance protein（ LRP）, epidermal growth factor receptor（EGRR） and HER-2 in breast infiltrating duct carcinoma, and evaluate its clinical significance. Methods Expression of LRP, EGFR, HER-2, and vascular endothelia/growth factor（ VEGF） in breast cancer tissues from 76 patients were detected by using immunohistoehemieal teehique. Results 1 ） The positive rate of LRP, EGFR, HER-2, and VEGF were 35.53%, 15.79% and 25% , respectively. There was no significant correlation among these factors in expression. 2） The expression of LRP was negatively correlated with the grade of tumor. 3） The expression of LRP, EGFR, HER-2 and VEGF was not correlated with lymph node metastasis. Conclusion Expression of LRP may play an important role in the malignant progression of the breast cancer, and could be used to judge the grade of breast cancer.